RedHill Biopharma enrolled the last patient into its phase II study of Bekinda 12 mg. Researchers are conducting a randomized, double-blind, placebo-controlled phase II study evaluating Bekinda’s safety and efficacy in 127 patients with irritable bowel syndrome with diarrhea.
RedHill Biopharma is hosting an analyst and investor R&D Day to discuss its drug Bekinda, a treatment for acute gastroenteritis and irritable bowel syndrome with diarrhea.
The endoscopy equipment market is likely to reach $35.3 billion by 2021, expanding at a 6.2 percent compound annual growth rate. Olympus Corp. and Boston Scientific Corp. are key vendors in the booming market.
The Society of American Gastrointestinal and Endoscopic Surgeons gave Mederi Therapeutics’ Stretta Therapy for gastroesophageal reflux disease a strong recommendation in a new clinical spotlight review guideline statement.
More articles on gastroenterology:
RedHill Biopharma enrolls last patient in Bekinda phase II study: 3 notes
Arkansas Gastroenterology Associates adds advanced practice nurse: 3 key notes
Endoscopy equipment market forecasted to reach $35.3B by 2021 — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.